Indian drugmakers Posh Chemicals and Promed Exports received warning letters from the U.S. FDA that indicated breaches in good manufacturing practices. Six India-based drug facilities have received the notices in the past three months. Lupin Pharma CEO Vinita Gupta said "all the FDA is trying to do is differentiate the good manufacturers from the not-so-good ones. Indian manufacturers are not being targeted."
Published in Brief: